Ocular Therapeutix (OCUL) Fundamental Analysis: Revenue, Earnings & Valuation

1.48 / 10

Underperform

Fundamental health is poor (1.5/10). Inventory turnover and cost‑of‑sales ratios are decent, but revenue growth is sharply negative (‑18.5% YoY). Leverage metrics are acceptable, while PB‑ROE and asset/value gaps are weak, leading to an Underperform rating.

Analysis Checks(5/10)

Revenue-MV

Value-2.93

Score1/3

Weight38.02%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-18.47

Score1/3

Weight-3.00%

1M Return-0.38%

Inventory turnover ratio

Value1.99

Score3/3

Weight-7.52%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value33.05

Score3/3

Weight14.22%

1M Return1.67%

PB-ROE

Value1.32

Score0/3

Weight25.79%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.14

Score3/3

Weight6.70%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.87%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-18.47

Score1/3

Weight-2.36%

1M Return-0.30%

Cost of sales ratio (%)

Value12.65

Score3/3

Weight2.22%

1M Return0.26%

Asset-MV

Value-0.55

Score0/3

Weight34.80%

1M Return4.00%

Is OCUL undervalued or overvalued?

OCUL scores 1.48/10 on fundamentals and holds a Premium valuation at present. Backed by its -54.85% ROE, -511.90% net margin, -6.95 P/E ratio, 2.82 P/B ratio, and -16.39% earnings growth, these metrics solidify its Underperform investment rating.